Home

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2021

British Association of Dermatologists - Clinical Guideline

Clinical practice guidelines for biologic therapy for psoriasis were updated in October 2020 by the British Association of Dermatologists. Use of Biologic Therapy . Biologic therapy for psoriasis should be initiated and supervised only by specialist physicians who are experienced in the diagnosis and treatment of psoriasis Smith CH, Yiu ZZ, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update. Br J Dermatol. 2020; 183 :628-37 Biologic Therapy for Psoriasis: BAD 2020 Guidelines - Page 2. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update, is published in the British Journal of Dermatology. DOI: https:. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020; 183(4):628-637 (ISSN: 1365-2133

[Guideline] Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020 Oct. 183 (4):628-637. . . [Guideline] Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.. The British Association of Dermatologists (BAD) has released a rapid update to their guidelines on the use of biologic therapies targeting TNF, IL12/23p40, IL17A, IL17RA and IL23p19 for the treatment of psoriasis, with consideration given to the specific needs of patients with psoriasis and psoriatic arthritis DOI: 10.1111/bjd.15665 Corpus ID: 207076915. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 @article{Smith2017BritishAO, title={British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017}, author={C. Smith and Z. Jabbar-Lopez and Z. Yiu and T. Bale and A. Burden and L. Coates and M. Cruickshank and T. Hadoke and E.

The European S3 Guidelines2017 [12], British Association of Dermatologists Guidelines for Biologic Therapy for Psoriasis 2017 13], American Academy of [Dermatology (AAD) and the National Psoriasis Foundation (NPF) guidelines 2019 (biologics and comorbidities) 14, 15], UK National Institute for Health and Car Quick and proven results for Psoriasis. 98% success with Philips TL01 Narrowband. Treatment for mild moderate and severe conditions. Philips 311nm n-UVB Lamp

British Association of Dermatologists Guidelines for

  1. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update. 20th March 2020 Dermatology, Dermatology Guidelines, General Practice, General Practice Guidelines, Guidelines for the Treatment & Management of Psoriasis,.
  2. This clinical guideline outlines the high cost drug treatment pathway for adult patients with psoriasis. June 2020 . Document Type Clinical Guideline Document Name North Central London High Cost Drug Treatment Guideline for Psoriasis Document Location https://www.ncl-mon.nhs British Association of Dermatologists Biologic Interventions.
  3. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update This information sheet does not list all of the side effects of risankizumab. If you wish to find out more about risankizumab please speak to your doctor, specialist nurse or pharmacist
  4. The 2020 British Association of Dermatologists guidelines for biologic therapy for psoriasis is a very useful resource and includes a decision guide for clinicians and patients to aid treatment choice. 3. Biological therapy can also be indicated in patients who have difficult localized disease at high-impact sites (face, hands, genital area.
  5. British Association of Dermatologists guidelines for biologic interventions for psoriasis 2017 external link opens in a new window Published by: British Association of Dermatologists Last published: 2020
  6. British Association of Dermatologists British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 Published: 2017 Dansk Dermatologisk Selskab Klinisk retningslinje for psoriasis Published: March 2016 European Dermatology Forum European S3-Guideline on the Systemic Treatment of Psoriasis Vulgaris—Update Apremilast.

Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628-37. CAS Article Google Scholar 3. Reid C, Cordingley L, Warren RB, Griffiths CEM Psoriasis clinical guideline. Psoriasis is a chronic, inflammatory multisystem disease, which affects up to 3.2% of the U.S. population. The guideline is based on current evidence, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients about benefits as well as risks that may be associated Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update Br J Dermatol , 183 ( 4 ) ( 2020 ) , pp. 628 - 637 CrossRef View Record in Scopus Google Schola

British Association of Dermatologists - Psoriasi

London (UK): British Association of Dermatologists (BAD); 2017 Apr. 395 p. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Implementation toolkit. London (UK): British Association of Dermatologists (BAD); 2017. 10 p. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 British Photodermatology Group Position Statements ; Sun Awareness Leaflets & Posters + Back. Leaflets & Posters ; Archive Clinical Guidelines ; Covid-19 + Back. Psoriasis + Back. Psoriasis 2007 ; Psoriasis 2013 ; Psoriasis 2017 ; Isotretinoin

Biologic Therapy for Psoriasis: BAD 2020 Guideline

The published guideline sections relate to biologic therapies, comorbidities, phototherapy, pediatric patients and systemic non-biologic therapies. The sixth section, topicals, is expected in Summer 2020. Together, they represent the first updating of psoriasis treatment guidelines in a decade British Photodermatology Group Position Statements ; Sun Awareness Leaflets & Posters + Back. Leaflets & Posters ; Archive Clinical Guidelines ; Covid-19 + Back. Self Isolation and Immunosuppressed Patients ; Psoriasis + Back. Psoriasis 2007 Guidelines for the Treatment of Psoriasis by Biological Products of Bulgarian Dermatological Society . [WWW document] 2013. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J.

Clinical Practice Guidelines for Psoriasis (BAD, 2020

  1. The British Association of Dermatologists (BAD) has updated its guideline on biologic therapy for psoriasis.The guideline, which is accredited by NICE, provides evidence-based recommendations on the use of biologic therapies (including adalimumab, etanercept, infliximab, ixekizumab, secukinumab, and ustekinumab) in adults, children, and young people for the treatment of psoriasis
  2. Buccheri L, Katchen BR, Karter AJ, et al. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133:711-715. Ormerod AD, Campalani E, Goodfield MJD. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162:952-963
  3. Prashant S, Dennis PW, Kenneth BG. Biologic Therapy for Psoriasis, The New Therapeutic Frontier. Arch Dermatol 2002; 138: 657-63. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23. Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis

He was heavily involved in the systematic review process underpinning the recommendations in the British Association of Dermatologists' guidelines for biological therapy for Psoriasis 2017 and the update in 2020, and currently serves as an Associate Editor for the Evidence-Based Dermatology section in the British Journal of Dermatology Biological agents approved for the treatment of psoriasis include: Risankizumab (Skyrizi®). Efalizumab (Raptiva®) was withdrawn from the market in 2009 and Alefacept (Amevive®) was withdrawn from the market in 2011. The biological agent medications used for psoriasis are also used for other severe health problems Guidelines on psoriasis from the British Association of Dermatologists (2017) state biologic therapy should be offered to people with psoriasis who require systemic therapy if: methotrexate and ciclosporin have failed, are not tolerated or are contraindicated (see NICE guidelines CG153) an R3 Offer people with psoriasis who are starting biologic therapy the opportunity to participate in long-term safety registries (in the U.K. and Republic of Ireland the British Association of Dermatologists Biologic Interventions Register, BADBIRI) Criteria for biologic therapy R

Since the association between occlusive vascular disease and psoriasis was proposed in the 1970s, 1 a myriad of epidemiological studies has confirmed a relationship between psoriatic inflammation, namely psoriasis and psoriatic arthritis, and adverse cardiovascular events. 2,3,4 This relationship is complex and was considered initially to be due to the higher prevalence of preexisting. I was heavily involved in the systematic review process underpinning the evidence-based recommendations in the British Association of Dermatologists (BAD) guidelines for biologic therapy for psoriasis 2017 and the updated guidelines in 2020. I am an associate editor for the evidence-based dermatology section in the British Journal of.

International guidelines. Rest of the world. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures external link opens in a new window. Drs Griffiths and Warren were funded in part by grant MR/L011808/1 from the Medical Research Council. The study group British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) is coordinated by The University of Manchester and funded by the British Association of Dermatologists (BAD)

The use of biological drugs in psoriasis patients prior to

Dose escalation and reduction of biologic treatments are frequent in clinical practice. The aim of this systematic review is to summarise evidence on dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real-world. A systematic review of real-world evidence on dose adjustment of biologics for plaque psoriasis was performed American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis . British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 . Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (2010) NICE Technology Appraisal Guidance 19

This document incorporates and summarises information from a number of publications, including guidelines published by the National Institute for Health and Care Excellence (NICE) [1,4], UpToDate [2,7,10,16,17,23,26] and the NZ Formulary [20,22]. It is relevant to the treatment of psoriasis in New Zealand. In this guideline, psoriasis refers to. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection, The British Journal of Dermatology 2012 (167)5:1145-1152. 4. Griffiths CE, Papp KA, Kimball AB, et al. Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 VOYAGE 1 trial. The proposed project will utilise data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). The BADBIR is a world-leading longitudinal, observational, web-based study of patients with moderate-to-severe psoriasis who are receiving either conventional systemic or biologic therapies for psoriasis

What are clinical practice guidelines on biologic therapy

  1. British Association of Dermatologists This website was designed by the British Association of Dermatologists to provide information and advice to people living with a skin condition. If you are healthcare professional looking for the main BAD site, to access our member's section, clinical guidelines, or service information, for example, then.
  2. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology 58 (5), 826-850. MHRA (2013) Aqueous cream: may cause skin irritation, particularly in children with eczema, possibly due to sodium lauryl sulfate content
  3. The German Psoriasis-Registry (PsoBest) with Pandora-system recommendations. during pandemic SARS-2 corona virus) National Institute for Health and Care Excellence (NICE) COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response. Société Français de Dermatologie
  4. British Journal of Dermatology: British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017..
  5. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58(5):826-50 (2008 May). Driessen RJ, Boezeman JB, van de Kerkhof PC, et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 160(3):670-5.

SKYRIZI ® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. 1 The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and. Biologic therapy has become one of the main treatments for psoriasis and has played an active and effective role in treating severe, refractory, and special types of psoriasis. 1-4 With the gradual increase in the number of biologic drugs approved for the treatment of psoriasis in China, and especially in light of the high prevalence of. National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5 15. Paller AS, Lund EB. Psoriasis in children: Management of chronic plaque psoriasis. UpToDate. Duffin KC, Levy ML. (Eds) February 19.

and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. Japanese Dermatological Association Guidelines. Journal of Dermatology. 2018; 45(11):1235-1270. 25. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009 A prospective cohort study was performed in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2019. We performed survival analysis and fitted a flexible parametric survival model for biologic discontinuation due to ineffectiveness 5. Smith CH, Jabbar-Lopez ZK, Yiu ZK, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628-636. doi: 10.1111/bjd.15665. 6. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis Smith CH, Jabbar Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177: 628-36. [Google Scholar

What are general guidelines on the management and

Psoriasis Workup: Approach Considerations, Laboratory

this document. If successful, continue uninterrupted therapy with follow up as recommended by the British Association of Dermatologists' Biologics Guidelines unless secondary failure, intolerance or new contraindication subsequently occurs. This applies at this stage and after each new biological agent is initiated Psoriasis guidelines (FOI) Produced by the Freedom of Information office Authored by Government of Jersey and published on 03 July 2020. Prepared internally, no external costs. Request . I am writing to enquire if your Jersey has any local guidelines for the treatment of psoriasis and/or psoriatic arthritis using biologic drugs Welcome to the BADBIR website. BADBIR is a clinical study to monitor the long-term safety of drugs used to treat psoriasis. Go to the Patient Portal. Find out more about the new BADBIR Patient Portal. The Patient Portal is currently in its pilot phase at a limited number of centres. Please only access it if you've been invited to do so The British Association of Dermatologists currently does not usually advise stopping or delaying immunosuppressant or biologic treatment before receiving the COVID-19 vaccine. There may be situations where your doctor advises reducing or stopping your treatment - for example, if your risk of COVID-19 is high and your psoriasis or psoriatic.

British Association of Dermatologists Publishes Rapid

Treatment for psoriasis usually helps to keep the condition under control. Most people can be treated by their GP. If your symptoms are particularly severe or not responding well to treatment, your GP may refer you to a skin specialist (dermatologist) Treatment options: guidelines. Below find guidelines from the British Association of Dermatologists (BAD), Primary Care Dermatology Society (PCDS) and the Scottish Intercollegiate Guidelines Network (SIGN) on the topic of treatment options

[PDF] British Association of Dermatologists guidelines for

  1. Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide, presenting at any age, and leading to a substantial burden for individuals and society. It is associated with several important medical conditions, including depression, psoriatic arthritis, and cardiometabolic syndrome. Its most common form, chronic plaque or psoriasis vulgaris, is a consequence of genetic.
  2. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic non-biological therapies external link opens in a new window. British Association of Dermatologists guidelines for biologic interventions for psoriasis external link opens in a new window. More guidelines
  3. An Analysis of Comparative Safety and Benefit-Risk Profile of Biologics and Oral Treatments for Moderate to Severe Plaque Psoriasis 03/04/2021 A study published in Journal of the American Academy of Dermatology aimed to compare the short-term (12-16 weeks) and long-term (48-56 weeks) safety and benefit-risk profiles of moderate to severe plaque.

forest plots British Association of Dermatologists - BAD

  1. Detecting Mycobacterium tuberculosis Infection, United States British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017* www William Anderson (collector) (431 words) [view diff] exact match in snippet view articl
  2. Optimizing Outcomes for Patients With Psoriasis, Spondyloarthropathies and Urticaria. Patients with psoriasis, spondyloarthropathies and urticaria often experience delay in diagnosis. Many patients receive suboptimal treatment, leading to disease progression and significant impact on their lives. As the treatment landscape is evolving rapidly.
  3. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2016; 38: 42-49. View article Google Schola
  4. Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse events or ineffectiveness in patients with psoriasis who had failed a first biologic therapy and switched to a second in a large, multicenter.

Psoriasis is a chronic immune-mediated skin disorder. Due to lack of clarity in its pathogenesis, a cure with existing treatment is a big challenge. Biologics, a revolutionary treatment, are potent immunomodulators that explicitly target the culprit cells of the immune system to achieve the maximum level of Psoriasis Area and Severity Index (PASI) score (75 to 90) and clear or almost clear. French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults F. Amatore A.‐P. Villani M. Tauber M. Viguier B. Guillot, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie

Introduction. Biological therapies (BT) are humanized proteins synthesized by genetic engineering. BT in psoriasis comprise anti-TNFα (adalimumab, etanercept, infliximab, certolizumab pegol) and anti-interleukins including ustekinumab (anti-IL-12/23), secukinumab and ixekizumab (anti- IL-17), brodalumab (anti-receptor of IL-17), guselkumab and risankizumab (anti-IL-23). 1, In this review, we compare PsA treatment recommendations or guidelines developed by one national organization [ACR and National Psoriasis Foundation (NPF) in 2018], one regional organization (EULAR in 2015), and one international organization (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis in 2015)

Psoriasis Treatment & Management: Approach Considerations

Clinical guidelines. The Academy is dedicated to promoting and encouraging dermatology research and the application of these findings to improving patient care. This includes the development of rigorous, evidence-based guidelines of care for dermatologic conditions. Learn more about the guideline development process Meggitt SJ, Anstey AV, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011 Oct;165(4):711-34. Wojnarowska F, Kirtschig G, Highet AS, et al. British Association of Dermatologists. Guidelines for the management of bullous pemphigoid British Association of Dermatologists (BAD) guidelines recommend that in the absence of relevant contraindications, both drugs should be considered equally as first-line biologic therapy for psoriasis, unless active psoriatic arthritis (PsA) is present, in which case adalimumab is preferred

Comparing the efficacy and tolerability of biologic

Psoriasis is an inflammatory autoimmune disease characterized by cutaneous lesions in plaques. It has been proposed that the immune response has a key role in the disease progression. Particularly, the Th17 cells through IL-17 can contribute to maintain the inflammatory process. The pathogenic Th17 phenotype has been described in human diseases and associated with high severity in inflammatory. Dermatology conference-2021 Osaka, Japan is going to be held during October 05-06, 2021. 26th Asia-Pacific Dermatology Conference is intended to provide insights on the emerging therapies and for various skin conditions has been chosen to foster the wide range of sub-specialties of Dermatology Conference will explore the advances in dermatology.The theme of the conference is Potential. Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by raised areas of abnormal skin. These areas are red, or purple on some people with darker skin, dry, itchy, and scaly. Psoriasis varies in severity from small, localized patches to complete body coverage. Injury to the skin can trigger psoriatic skin changes at that spot, which is known as the Koebner phenomenon

Dr

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 BJD/Wiley July 1, 2017 British Association of Dermatologists' guidelines for the management of contact dermatitis 201 Dr Proudfoot is a member of the British Association of Dermatologists, the British Society of Paediatric Dermatology, the Society for Pediatric Dermatology and the Royal Society of Medicine. She consults on all general dermatology in both adults and children including eczema, acne, psoriasis, alopecia, vascular lesions, birthmarks and mole. Dermatology Medicine 2022. Conference Series LLC Ltd organizes 1000+ Global Events every Year across different continents like USA, Europe & Asia with support from 1000+ scientific societies and Publishes, 700+ Open access journals which contain over 1,00,000 well-known personalities, reputed researchers at editorial board and organizing committee penal Hevey2and B. Kirby, Targeted cognitive behavioural therapy is effectivein reducing alcohol misuse in patients withmoderate to severe psoriasis, British Journal of Dermatology, British Association of Dermatologists Annual Conference, Liverpool, July 2013, 169, (Suppl 1), Wiley, 2013, pp55-Poster, 201

Clinical Dermatology Research Journal (CDRJ) is a peer-reviewed scholarly journal that aims to publish the most complete and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in all areas of Dermatology and clinical practices related to Dermatology The American Academy of Dermatology was founded in 1938. It is the largest, most influential and representative dermatology group in the United States. With a membership of more than 19,000, it represents virtually all practicing dermatologists in the United States, as well as a growing number of international dermatologists. More The aim of this review is to compare and contrast evidence-based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis. Clinical practice guidelines from the American Academy of Dermatology, National Psoriasis Foundation, British Association of Dermatologists, and European S3 were reviewed. National Eczema Association | 505 San Marin Drive, #B300 | Novato, CA 94945 415-499-3474 or 800-818-7546 NEA is a qualified 501(c)(3) EIN 93-098884 Psoriasis is a chronic autoimmune skin disease. There are many types of psoriasis: guttate, plaque, inverse, erythrodermic, and pustular. Red dry flakes, silvery-white skin scales, and plaques of raised skin are common symptoms and signs. Read how diet impacts psoriasis, and learn if it's contagious

Dermatology UC

Mark G. Lebwohl, M.D., is an American dermatologist and author and the Waldman Professor and Chairman of the Kimberly and Eric J. Waldman Department of and Chairman of the Department of Dermatology at the Mount Sinai Hospital in New York City. Lebwohl's books include the book on dermatologic therapy, Treatment of Skin Disease (ISBN 0323036031), as well as Atlas of the Skin and Systemic Disease.

Taniela BALE | Fiji National University, Suva | FNUA Rare Eyelid Dermatitis Allergen: Shellac in a PopularMastocytosis: Background, Pathophysiology, EtiologyJublia (efinaconazole) dosing, indications, interactions